Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.71 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.69 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241720 | 0.96 | ROCK2 (0.70) | ROCK2ROCK1CDC42BPACYP3A4CYP2D6 | |
| SCHEMBL3249778 | 0.95 | ROCK2 (0.74) | ROCK2ROCK1CDC42BPACYP3A4CYP2D6 | |
| SCHEMBL3247662 | 0.94 | ROCK2 (0.75) | ROCK2ROCK1CDC42BPACYP3A4CYP2D6 | |
| SCHEMBL3242776 | 0.93 | ROCK2 (0.77) | ROCK2ROCK1CDC42BPACYP3A4CYP2D6 | |
| SCHEMBL3242868 | 0.91 | ROCK2 (0.82) | ROCK2ROCK1CDC42BPACYP3A4CYP2D6 | |
| SCHEMBL3238655 | 0.90 | ROCK2 (0.71) | ROCK2ROCK1CDC42BPACYP3A4CYP2D6 | |
| SCHEMBL3130135 | 0.90 | ROCK2 (0.80) | ROCK2ROCK1CDC42BPACYP3A4CYP2D6 | |
| SCHEMBL3249876 | 0.90 | ROCK2 (0.80) | ROCK2ROCK1CDC42BPACYP3A4CYP2D6 | |
| SCHEMBL3121595 | 0.89 | ROCK2 (0.80) | ROCK2ROCK1CDC42BPACYP3A4CYP2D6 | |
| SCHEMBL3126880 | 0.88 | ROCK2 (0.80) | ROCK2ROCK1CDC42BPACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3600324-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
| CN-110662543-A | Medicaments and compositions for treating ocular diseases | 灰色视觉公司 | 2020-01-07 | — | — | CN | disclosed |
| WO-2018175922-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | ROCK2 400/4885ROCK1 197/4885CDC42BPA 2048/4885 |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | ROCK2 400/4885ROCK1 197/4885CDC42BPA 2048/4885 |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | ROCK2 400/4885ROCK1 197/4885CDC42BPA 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.